Cleo Diagnostics (ASX:COV) EV-to-EBITDA : (As of May. 12, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cleo Diagnostics's enterprise value is A$23.85 Mil. Cleo Diagnostics does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Cleo Diagnostics's EV-to-EBITDA at this moment.

The historical rank and industry rank for Cleo Diagnostics's EV-to-EBITDA or its related term are showing as below:

ASX:COV' s EV-to-EBITDA Range Over the Past 10 Years
Min: -66.18 Med: 0 Max: 0
Current: -6.39

ASX:COV's EV-to-EBITDA is ranked worse than
100% of 483 companies
in the Medical Devices & Instruments industry
Industry Median: 16.47 vs ASX:COV: -6.39

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Cleo Diagnostics's stock price is A$0.175. Cleo Diagnostics does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Cleo Diagnostics's PE Ratio at this moment.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Cleo Diagnostics EV-to-EBITDA Historical Data

The historical data trend for Cleo Diagnostics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics EV-to-EBITDA Chart

Cleo Diagnostics Annual Data

Trend

Jun23

EV-to-EBITDA

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
EV-to-EBITDA	-	-	-

Competitive Comparison of Cleo Diagnostics's EV-to-EBITDA

For the Medical Devices subindustry, Cleo Diagnostics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's EV-to-EBITDA falls into.

Cleo Diagnostics EV-to-EBITDA Calculation

Cleo Diagnostics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	23.848	/
	=

Cleo Diagnostics (ASX:COV) EV-to-EBITDA Explanation

Cleo Diagnostics's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.175	/
	=

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Cleo Diagnostics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines